Revive Therapeutics announced final results from its research project with the University of Wisconsin-Madison for the development of a novel cannabinoid delivery technology.
Revive Therapeutics (TSXV:RVV; OTCQB:RVVTF) announced final results from its research project with the University of Wisconsin-Madison for the development of a novel cannabinoid delivery technology.
As quoted in the press release:
“The successful demonstration of the cannabinoid delivery technology is a significant milestone for Revive as it positions us to develop, partner and commercialize unique medical cannabis and pharmaceutical cannabinoid therapies in large global market opportunities such as in pain, dermatology, and wound healing while complementing our research efforts in cannabinoid treatments for liver diseases, thus solidifying Revive as a unique company offering novel product and technology solutions for the medical cannabis and pharmaceutical sectors,” said Craig Leon, Chief Executive Officer of Revive.
“I am very pleased with the outcome of the research program as we have successfully demonstrated that the delivery technology in combination with synthetic cannabidiol is able to effectively reduce inflammation and be delivered in an efficient and controlled way thus offering a novel and potentially effective therapeutic option for a broad range of indications, such as pain, that would benefit from cannabinoid therapies,” said Dr. Jess D. Reed, Professor of Animal Nutrition at the University of Wisconsin-Madison.